Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

migrator

Updated:2nd Sep, 2021 at 6:28 PM

New Delhi

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

''Granules is working closely with DRDO team to launch the product in India at the earliest,'' it added. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said. Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research &amp; Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Also Read

Election Commission deploys 327 observers across TN in major poll push

Iran allows Pakistani oil tanker passage through Strait of Hormuz

11 months on, Airport-Kilambakkam Metro DPR still stuck with Centre

CM Stalin closes Pondy ticket interview sans Congress deal

Lebanon proposes first direct talks with Israel in decades. It might be too late

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).